US Stock MarketDetailed Quotes

REGN Regeneron Pharmaceuticals

Watchlist
  • 996.030
  • -2.200-0.22%
Trading Oct 18 15:16 ET
109.80BMarket Cap26.37P/E (TTM)

Regeneron Pharmaceuticals Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
(Q3)Sep 30, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
-65.38%354M
10.60%1.51B
-8.39%4.59B
-36.64%1.09B
77.18%1.11B
81.15%1.02B
-34.93%1.37B
-29.18%5.01B
-27.51%1.72B
-81.58%628.9M
Net income from continuing operations
47.90%1.43B
-11.71%722M
-8.87%3.95B
-3.13%1.16B
-23.40%1.01B
13.65%968.4M
-15.99%817.8M
-46.28%4.34B
-46.29%1.2B
-19.39%1.32B
Operating gains losses
-1,370.55%-392.6M
17.71%196.1M
623.91%266.4M
27.92%-58.1M
150.10%127M
-81.43%30.9M
-18.53%166.6M
109.51%36.8M
-158.58%-80.6M
-965.19%-253.5M
Depreciation and amortization
17.07%120.7M
14.67%114.1M
23.32%421M
12.89%113M
13.82%105.4M
38.58%103.1M
33.92%99.5M
19.29%341.4M
34.36%100.1M
26.50%92.6M
Deferred tax
43.57%-118.1M
12.06%-190.4M
-12.25%-837.8M
-2.36%-286.3M
-46.67%-125.7M
-34.17%-209.3M
3.78%-216.5M
-407.41%-746.4M
-35.84%-279.7M
-1,324.29%-85.7M
Other non cash items
-134.88%-3M
-99.51%100K
-100.02%-100K
-110.36%-17.5M
-119.44%-11.8M
-96.55%8.6M
-75.56%20.6M
-1.00%563M
-44.46%169M
-15.46%60.7M
Change In working capital
-1,017.47%-908.5M
82.86%440.5M
61.32%-94.1M
-116.07%-61.4M
71.18%-192.3M
89.59%-81.3M
-70.74%240.9M
87.30%-243.3M
207.48%382M
-145.60%-667.2M
-Change in receivables
-18,200.00%-494.1M
112.66%446.8M
-147.87%-338.8M
-137.66%-82.7M
-19.80%-463.5M
99.16%-2.7M
-82.46%210.1M
136.72%707.8M
137.57%219.6M
-125.11%-386.9M
-Change in inventory
-81.08%-181.8M
-232.91%-155.8M
60.99%-271.7M
67.22%-47.3M
65.46%-77.2M
58.18%-100.4M
47.18%-46.8M
-40.91%-696.5M
11.85%-144.3M
-104.86%-223.5M
-Change in prepaid assets
-15,379.41%-526.3M
-1,316.36%-77.9M
19.18%-120.1M
778.61%164.3M
-327.31%-275.5M
98.60%-3.4M
87.72%-5.5M
38.26%-148.6M
-75.43%18.7M
410.77%121.2M
-Change in payables and accrued expense
415.37%204.6M
-7.14%110.5M
532.51%598.6M
-139.90%-138.7M
460.95%578.6M
152.72%39.7M
147.52%119M
-115.98%-138.4M
-4.95%347.6M
-309.00%-160.3M
-Change in other working capital
714.48%89.1M
425.63%116.9M
16.98%37.9M
172.15%43M
355.93%45.3M
-114.47%-14.5M
-477.89%-35.9M
126.96%32.4M
-21.63%-59.6M
-176.56%-17.7M
Cash from discontinued investing activities
Operating cash flow
-65.38%354M
10.60%1.51B
-8.39%4.59B
-36.64%1.09B
77.18%1.11B
81.15%1.02B
-34.93%1.37B
-29.18%5.01B
-27.51%1.72B
-81.58%628.9M
Investing cash flow
Cash flow from continuing investing activities
76.66%-557.2M
-615.78%-1.69B
15.84%-3.19B
96.44%-66.2M
-358.09%-496.3M
-476.69%-2.39B
86.18%-235.7M
29.72%-3.78B
7.70%-1.86B
107.89%192.3M
Capital expenditure reported
-59.73%-180.5M
24.86%-133.9M
-21.78%-718.6M
-65.18%-251.4M
-23.51%-176M
26.43%-113M
-25.67%-178.2M
-6.92%-590.1M
1.74%-152.2M
-6.98%-142.5M
Net intangibles purchase and sale
-45.45%-30.4M
72.35%-27.9M
79.76%-207.8M
37.90%-62.1M
97.42%-23.9M
---20.9M
---100.9M
---1.03B
---100M
---926.8M
Net business purchase and sale
----
----
76.16%-54.9M
---3.8M
---51.1M
----
----
---230.3M
--0
----
Net investment purchase and sale
83.96%-361.4M
-3,614.52%-1.53B
-13.75%-2.2B
115.64%251.1M
-119.44%-245.3M
-7,410.00%-2.25B
102.78%43.4M
59.91%-1.94B
13.58%-1.61B
154.72%1.26B
Cash from discontinued investing activities
Investing cash flow
76.66%-557.2M
-615.78%-1.69B
15.84%-3.19B
96.44%-66.2M
-358.09%-496.3M
-476.69%-2.39B
86.18%-235.7M
29.72%-3.78B
7.70%-1.86B
107.89%192.3M
Financing cash flow
Cash flow from continuing financing activities
22.16%-478.1M
114.60%47.1M
-77.41%-1.79B
-80.17%-446.1M
43.82%-407.3M
-507.52%-614.2M
-598.45%-322.5M
-0.32%-1.01B
72.69%-247.6M
-288.12%-725M
Net common stock issuance
22.16%-478.1M
114.60%47.1M
-77.41%-1.79B
-80.17%-446.1M
43.82%-407.3M
-507.52%-614.2M
-598.45%-322.5M
-0.32%-1.01B
72.69%-247.6M
-288.12%-725M
Cash from discontinued financing activities
Financing cash flow
22.16%-478.1M
114.60%47.1M
-77.41%-1.79B
-80.17%-446.1M
43.82%-407.3M
-507.52%-614.2M
-598.45%-322.5M
-0.32%-1.01B
72.69%-247.6M
-288.12%-725M
Net cash flow
Beginning cash position
-33.57%2.61B
-12.23%2.74B
7.64%3.12B
-38.36%2.16B
-42.80%1.95B
16.96%3.93B
7.64%3.12B
31.30%2.9B
1.74%3.5B
63.51%3.41B
Current changes in cash
65.57%-681.3M
-115.75%-127.5M
-272.25%-381.2M
249.82%577.4M
119.02%210.7M
-4,105.47%-1.98B
75.54%809.4M
-67.96%221.3M
29.52%-385.4M
-92.93%96.2M
Effect of exchange rate changes
25.00%-300K
---500K
---400K
--200K
---200K
---400K
--0
--0
--0
--0
End cash Position
-1.10%1.93B
-33.57%2.61B
-12.23%2.74B
-12.23%2.74B
-38.36%2.16B
-42.80%1.95B
16.96%3.93B
7.64%3.12B
7.64%3.12B
1.74%3.5B
Free cash flow
-83.89%143.1M
24.09%1.35B
7.93%3.67B
-47.11%776.2M
307.63%914.4M
116.29%888.5M
-44.46%1.09B
-47.96%3.4B
-33.82%1.47B
-113.43%-440.4M
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022(Q3)Sep 30, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities -65.38%354M10.60%1.51B-8.39%4.59B-36.64%1.09B77.18%1.11B81.15%1.02B-34.93%1.37B-29.18%5.01B-27.51%1.72B-81.58%628.9M
Net income from continuing operations 47.90%1.43B-11.71%722M-8.87%3.95B-3.13%1.16B-23.40%1.01B13.65%968.4M-15.99%817.8M-46.28%4.34B-46.29%1.2B-19.39%1.32B
Operating gains losses -1,370.55%-392.6M17.71%196.1M623.91%266.4M27.92%-58.1M150.10%127M-81.43%30.9M-18.53%166.6M109.51%36.8M-158.58%-80.6M-965.19%-253.5M
Depreciation and amortization 17.07%120.7M14.67%114.1M23.32%421M12.89%113M13.82%105.4M38.58%103.1M33.92%99.5M19.29%341.4M34.36%100.1M26.50%92.6M
Deferred tax 43.57%-118.1M12.06%-190.4M-12.25%-837.8M-2.36%-286.3M-46.67%-125.7M-34.17%-209.3M3.78%-216.5M-407.41%-746.4M-35.84%-279.7M-1,324.29%-85.7M
Other non cash items -134.88%-3M-99.51%100K-100.02%-100K-110.36%-17.5M-119.44%-11.8M-96.55%8.6M-75.56%20.6M-1.00%563M-44.46%169M-15.46%60.7M
Change In working capital -1,017.47%-908.5M82.86%440.5M61.32%-94.1M-116.07%-61.4M71.18%-192.3M89.59%-81.3M-70.74%240.9M87.30%-243.3M207.48%382M-145.60%-667.2M
-Change in receivables -18,200.00%-494.1M112.66%446.8M-147.87%-338.8M-137.66%-82.7M-19.80%-463.5M99.16%-2.7M-82.46%210.1M136.72%707.8M137.57%219.6M-125.11%-386.9M
-Change in inventory -81.08%-181.8M-232.91%-155.8M60.99%-271.7M67.22%-47.3M65.46%-77.2M58.18%-100.4M47.18%-46.8M-40.91%-696.5M11.85%-144.3M-104.86%-223.5M
-Change in prepaid assets -15,379.41%-526.3M-1,316.36%-77.9M19.18%-120.1M778.61%164.3M-327.31%-275.5M98.60%-3.4M87.72%-5.5M38.26%-148.6M-75.43%18.7M410.77%121.2M
-Change in payables and accrued expense 415.37%204.6M-7.14%110.5M532.51%598.6M-139.90%-138.7M460.95%578.6M152.72%39.7M147.52%119M-115.98%-138.4M-4.95%347.6M-309.00%-160.3M
-Change in other working capital 714.48%89.1M425.63%116.9M16.98%37.9M172.15%43M355.93%45.3M-114.47%-14.5M-477.89%-35.9M126.96%32.4M-21.63%-59.6M-176.56%-17.7M
Cash from discontinued investing activities
Operating cash flow -65.38%354M10.60%1.51B-8.39%4.59B-36.64%1.09B77.18%1.11B81.15%1.02B-34.93%1.37B-29.18%5.01B-27.51%1.72B-81.58%628.9M
Investing cash flow
Cash flow from continuing investing activities 76.66%-557.2M-615.78%-1.69B15.84%-3.19B96.44%-66.2M-358.09%-496.3M-476.69%-2.39B86.18%-235.7M29.72%-3.78B7.70%-1.86B107.89%192.3M
Capital expenditure reported -59.73%-180.5M24.86%-133.9M-21.78%-718.6M-65.18%-251.4M-23.51%-176M26.43%-113M-25.67%-178.2M-6.92%-590.1M1.74%-152.2M-6.98%-142.5M
Net intangibles purchase and sale -45.45%-30.4M72.35%-27.9M79.76%-207.8M37.90%-62.1M97.42%-23.9M---20.9M---100.9M---1.03B---100M---926.8M
Net business purchase and sale --------76.16%-54.9M---3.8M---51.1M-----------230.3M--0----
Net investment purchase and sale 83.96%-361.4M-3,614.52%-1.53B-13.75%-2.2B115.64%251.1M-119.44%-245.3M-7,410.00%-2.25B102.78%43.4M59.91%-1.94B13.58%-1.61B154.72%1.26B
Cash from discontinued investing activities
Investing cash flow 76.66%-557.2M-615.78%-1.69B15.84%-3.19B96.44%-66.2M-358.09%-496.3M-476.69%-2.39B86.18%-235.7M29.72%-3.78B7.70%-1.86B107.89%192.3M
Financing cash flow
Cash flow from continuing financing activities 22.16%-478.1M114.60%47.1M-77.41%-1.79B-80.17%-446.1M43.82%-407.3M-507.52%-614.2M-598.45%-322.5M-0.32%-1.01B72.69%-247.6M-288.12%-725M
Net common stock issuance 22.16%-478.1M114.60%47.1M-77.41%-1.79B-80.17%-446.1M43.82%-407.3M-507.52%-614.2M-598.45%-322.5M-0.32%-1.01B72.69%-247.6M-288.12%-725M
Cash from discontinued financing activities
Financing cash flow 22.16%-478.1M114.60%47.1M-77.41%-1.79B-80.17%-446.1M43.82%-407.3M-507.52%-614.2M-598.45%-322.5M-0.32%-1.01B72.69%-247.6M-288.12%-725M
Net cash flow
Beginning cash position -33.57%2.61B-12.23%2.74B7.64%3.12B-38.36%2.16B-42.80%1.95B16.96%3.93B7.64%3.12B31.30%2.9B1.74%3.5B63.51%3.41B
Current changes in cash 65.57%-681.3M-115.75%-127.5M-272.25%-381.2M249.82%577.4M119.02%210.7M-4,105.47%-1.98B75.54%809.4M-67.96%221.3M29.52%-385.4M-92.93%96.2M
Effect of exchange rate changes 25.00%-300K---500K---400K--200K---200K---400K--0--0--0--0
End cash Position -1.10%1.93B-33.57%2.61B-12.23%2.74B-12.23%2.74B-38.36%2.16B-42.80%1.95B16.96%3.93B7.64%3.12B7.64%3.12B1.74%3.5B
Free cash flow -83.89%143.1M24.09%1.35B7.93%3.67B-47.11%776.2M307.63%914.4M116.29%888.5M-44.46%1.09B-47.96%3.4B-33.82%1.47B-113.43%-440.4M
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ----Unqualified Opinion--------Unqualified Opinion----

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data

Concept Infectious Disease
Infectious Disease
Intraday0.00%